ABSTRACT
INTRODUCTION
Acute respiratory infections are still a major health problem in most developing countries. Group-A streptococci are the leading cause of acute bacterial pharyngitis [2] and primary skin infections. Impetigo is the most frequently occurring disease, especially in tropical climates. Inappropriate antibiotic treatment for pharyngitis is becoming a major issue; hence only true group-A beta-hemolytic streptococcal infections proven by rapid antigen test or culture should be treated with antibiotics.
Penicillin remains the treatment of choice for group-A beta-hemolytic streptococci (GABHS) pharyngitis, [1, 2, 5] and macrolide are recommended only for patients who are allergic to penicillin. Erythromycin resistance in GABHS ranges from as low as 1.3%-5% to as high as >45% as reported from outbreaks in Finland, [9] Sweden, [6] and Japan. [12] High rates of resistance have also been reported sporadically from Australia (17%), [15] United Kingdom (22.8%), [19] Taiwan (rate not speciÞ ed), and Italy (40%). [9] Resistance to tetracycline and co-trimoxazol has been reported to be high, making them virtually unusable as an alternative for the treatment of GABHS infection. [9] Antimicrobial drugs for GABHS are used to avoid suppurative complication, prevent rheumatic fever, abort person-to-person transmission, and diminish the signs and symptoms associated with these infections. The current resistance pattern of GABHS in India has never been evaluated. Hence we planned this study to determine the prevalence and degree of antibacterial resistance in GABHS isolates.
MATERIALS AND METHODS

Study population
Children with acute pharyngo-tonsillitis attending the pediatric OPD who had not received antibiotic in the preceding 1 week and who consented to participate were prospectively enrolled over a period of 1 year (July 2005 to June 2006). An institutional ethical clearance was obtained.
Sample collection and transport
Throat swabs were collected. Each swab was transported to microbiology laboratory in screwcapped test tube with Stuart's transport medium within half an hour.
Culture, identification, and antibiotic susceptibility testing Throat swab from each patient was plated on trypticase soy blood agar with 5% sheep blood. Inoculated plates were incubated overnight at 37°C under 5% CO 2 effect and examined for the presence of GABHS by the formation of distinct zones of beta-hemolysis around colonies. [7] GABHS strains were identiÞ ed on the basis of zone diameter around bacitracin disk (10 µg/ disk) on susceptibility testing as recommended by CLSI. [4] In this study, we deÞ ned GABHS strains only using the bacitracin test, since serotyping is not available in our routine practice. Bacterial colonies producing no hemolysis were considered as bacitracin resistant.
Disks susceptibility testing was performed according to the guideline of CLSI. [4] MuellerHinton sheep blood agar was inoculated with a suspension of organism. Disks with 15 µg/disk of erythromycin, 30 µg/disk of tetracycline, 50 µg/disk of chloramphenicol, 25 µg/disk of cotrimoxazol, and 10 units/disk of penicillin G were dispensed on the Muller Hinton Agar (MHA) with 5% sheep blood, and zone diameters were determined according to CLSI standard.
Minimum inhibitory concentration
Susceptibility of the strain to erythromycin, chloramphenicol, tetracycline, co-trimoxazol, and penicillin G was tested by broth dilution method. All the antibiotics were procured from Himedia (Mumbai, India). The antibiotics were tested at concentrations ranging from 0.012 to 0.125 µg of penicillin/mL, 0.125 to 4 µg of erythromycin/ mL, 0.125 to 16 µg of tetracycline/mL, 0.25 to 2 µg of chloramphenicol/mL, and 0.25 to 4 µg of co-trimoxazol/mL. The following Minimum inhibitory concentration (MIC) breakpoints were adopted according to CLSI guidelines [4] : penicillinsusceptible, ≤0.125 µg/mL; and resistant, ≥0.25 µg/mL; erythromycin-susceptible, ≤0.25 µg/mL; and resistant, ≥1 µg/mL; tetracyclinesusceptible, ≤2 µg/mL; and resistant, ≥8 µg/ mL; chloramphenicol-susceptible, ≤4 µg/mL; and resistant, ≥16 µg/mL; and co-trimoxazolsusceptible, ≤1 µg/mL; and resistant, ≥2 µg/ mL.
A control plate was inoculated for each isolate to conÞ rm the purity of the culture and the initial inoculum density. MICs were interpreted by using the CLSI breakpoints for streptococci.
Data analysis
Data was analyzed on WHO net microbiology laboratory database software (version 5.1).
RESULTS AND DISCUSSION
Of the 435 children (age, 2-12 years) enrolled in the study, 55 (12.6%) were culture positive for GABHS [ Table 1 ]. Of these 55, 6 isolates lost their viability during storage and subculturing. Resistance pattern of remaining 49 isolates was tested against penicillin G, erythromycin, chloramphenicol, tetracycline, and co-trimoxazole. The overall rate of macrolide resistance was 10.2%. Of these 49 GABHS isolates, 12 (24.4%) were resistant to tetracycline, followed by co-trimoxazole (6, 12.2%) and erythromycin (5, 10.2%) [ Table  2 ]. All the isolates were sensitive to penicillin G and chloramphenicol. Tetracycline and cotrimoxazol resistances were 24.5% and 12.2% respectively [ Table 2 ].
The MIC 50 for erythromycin-resistant strains was 0.5 µg/mL (range, 0.125-8 µg/mL), and MIC 90 was 8 µg/mL (range, 0.125-8 µg/mL). The values of MIC 50 for tetracycline-and cotrimoxazole-resistant strains were 4 µg/mL (range, 0.125-32 µg/mL) and 2 µg/mL (range, 0.25-8 µg/mL) respectively, while values of MIC 90 for these antibiotics were 16 µg/mL (range, 0.125-32 µg/mL) and 4 µg/mL (range, 0.25-8 µg/mL) respectively. MIC values for antimicrobials are given in Table 2 .
Our study shows that prevalence of antibioticresistant group-A streptococci has emerged rapidly in northern India. [13] Several reports of erythromycin resistance ranging from 1% to 18% among group-A streptococci have been published. [6, [12] [13] [14] [15] [16] [17] An increasing trend toward erythromycin resistance was reported from Japan, [6] where the frequency of erythromycinresistant group-A streptococci Þ rst increased from 70% to 80% and then decreased once the use of erythromycin was reduced. Erythromycin resistance ranges from as low as 1.3%-5% to as high as >45% during outbreaks in Finland, [14] Sweden, [6] and Japan. [12] High rates of resistance have also been reported sporadically in Australia (17%) [15] and United Kingdom (22.8%). [9] Prevalence of macrolide resistance was 10.2% in our study. The importance of identifying macrolide resistance in GABHS is dependent upon whether these antibiotics are used for treatment and if in vitro resistance results in clinical failure. At present, erythromycin is recommended as alternative treatment for patients with GABHS pharyngitis who are allergic to penicillin. [1, 5] A continuous surveillance will be helpful in management of such cases.
The present study reports 24.5% tetracycline resistance in GABHS. In 1954, Lowbury and Cason [17] reported the Þ rst isolate of GABHS from a unit in Birmingham, England, that was resistant to tetracycline. Subsequent reports showed that 5% to 25% of the GABHS isolated from US [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and 17% of the GABHS isolated from Spain were resistant to tetracycline. The prevalence of co-trimoxazol resistance found in our study was 12.2%. Though resistance to this drug is low, it cannot be used because of the intrinsic resistance [17] of group-A streptococci. All isolates were susceptible to chloramphenicol. No GABHS were found to be penicillin resistant in our study, reinforcing the fact that the penicillin resistance has not developed in this organism in northern India, in spite of frequent penicillin use.
